We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
- Authors
Kabra, Madhusudan; Barber, Tristan J; Allavena, Clotilde; Marcelin, Anne-Geneviève; Giambenedetto, Simona Di; Pasquau, Juan; Gianotti, Nicola; Llibre, Josep M; Rial-Crestelo, David; Miguel-Buckley, Rosa De; Blick, Gary; Turner, Matthew; Harrison, Cale; Wynne, Tammy; Verdier, Gustavo; Parry, Chris M; Jones, Bryn; Okoli, Chinyere; Donovan, Cynthia; Priest, Julie
- Abstract
Background To investigate the impact of the M184V/I mutation on virologic response to dolutegravir plus lamivudine (DTG + 3TC) in suppressed-switch populations, a meta-analysis was performed using virologic outcomes from people with human immunodeficiency virus type 1 (PWH) with and without M184V/I before DTG + 3TC switch in real-world studies identified via systematic literature review. Sensitivity analyses were performed using data from PWH with M184V/I in interventional studies identified via targeted literature review. Methods Single-arm meta-analyses using common- and random-effects models were used to estimate proportions of PWH with virologic failure (VF) among real-world populations with and without M184V/I and interventional study participants with M184V/I at 24, 48, and 96 weeks. Results Literature reviews identified 5 real-world studies from 3907 publications and 51 abstracts meeting inclusion criteria and 5 interventional studies from 1789 publications and 3 abstracts. All time points had low VF incidence in PWH with M184V/I (real-world: 1.43%–3.81%; interventional: 0.00%) and without (real-world: 0.73%–2.37%). Meta-analysis–estimated proportions (95% confidence interval) with VF were low at weeks 24, 48, and 96, respectively, for PWH with M184V/I (real-world: 0.01 [.00–.04], 0.03 [.01–.06], and 0.04 [.01–.07]; interventional: 0.00 [.00–.02], 0.00 [.00–.01], and 0.00 [.00–.03]) and without (real-world: 0.00 [.00–.02], 0.02 [.01–.04], and 0.02 [.00–.05]). One real-world study (n = 712) reported treatment-emergent M184V at VF in 1 of 652 (0.15%) PWH without prior M184V/I. Conclusions Results suggest that prior M184V/I has minimal impact on virologic suppression after switching to DTG + 3TC and provide reassurance when considering switching regimens in virologically suppressed PWH with incomplete treatment history or limited treatment options.
- Subjects
LITERATURE reviews; HIV; LAMIVUDINE; DOLUTEGRAVIR; CLINICAL trials
- Publication
Open Forum Infectious Diseases, 2023, Vol 10, Issue 11, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofad526